Study Summary
The aim of this prospective study is to evaluate the feasibility and efficacy of metoprolol, a beta-1 adrenergic receptor blocker, in the treatment of cytokine release syndrome (CRS) caused by chimeric antigen receptor T (CAR T) cell infusions, its effects on the serum levels of Interleukin-6 (IL-6) and other cytokines.
Want to learn more about this trial?
Request More InfoInterventions
MetoprololDRUG
Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
metoprolol, infliximab, etanercept, tocilizumab and/or other agentsDRUG
During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Biotherapeutic Department of Chinese PLA General Hospital | Beijing | Beijing Municipality | China |